Cargando…

SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential

BACKGROUND: Metabolic reprogramming plays an essential role on lymphoma progression. Dysregulation of glutamine metabolism is implicated in natural-killer T-cell lymphoma (NKTCL) and tumor cell response to asparaginase-based anti-metabolic treatment. METHODS: To understand the metabolomic alteration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Jie, Wang, Nan, Zhong, Hui-Juan, Cui, Bo-Wen, Cheng, Shu, Sun, Rui, Chen, Jia-Yi, Xu, Peng-Peng, Cai, Gang, Wang, Li, Sun, Xiao-Jian, Huang, Jin-Yan, Zhao, Wei-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511843/ https://www.ncbi.nlm.nih.gov/pubmed/34628354 http://dx.doi.org/10.1016/j.ebiom.2021.103614

Ejemplares similares

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
por: Ni, Rui, et al.
Publicado: (2023)

WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia
por: Hu, Juncheng, et al.
Publicado: (2020)

SLC1A3 facilitates Newcastle disease virus replication by regulating glutamine catabolism
por: Liu, Panrao, et al.
Publicado: (2022)

miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma
por: Luo, Meiying, et al.
Publicado: (2018)

Targeting Glutamine Addiction in Gliomas
por: Obara-Michlewska, Marta, et al.
Publicado: (2020)

Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1‐driven acute lymphoblastic leukemia
por: Nguyen, Tra Ly, et al.
Publicado: (2021)

α-Ketoglutaramate—A key metabolite contributing to glutamine addiction in cancer cells
por: Cooper, Arthur J. L., et al.
Publicado: (2022)

SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
por: Guo, Chuansheng, et al.
Publicado: (2023)

Loss of the tumor suppressor Hace1 leads to ROS-dependent glutamine addiction
por: Cetinbas, Naniye, et al.
Publicado: (2014)

SLC7A11, a potential immunotherapeutic target in lung adenocarcinoma
por: Shan, Qingqing, et al.
Publicado: (2023)

A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer
por: Li, He, et al.
Publicado: (2022)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
por: Zhang, Pei, et al.
Publicado: (2023)

Multimeric immunotherapeutic complexes activating natural killer cells towards HIV-1 cure
por: Schober, Rafaëla, et al.
Publicado: (2023)

Circ_0000463 contributes to the progression and glutamine metabolism of non‐small‐cell lung cancer by targeting miR‐924/SLC1A5 signaling
por: Liu, Yunzhong, et al.
Publicado: (2021)

Glutamine Transporter SLC1A5 Regulates Ionizing Radiation-Derived Oxidative Damage and Ferroptosis
por: Yuan, Zhuhui, et al.
Publicado: (2022)

The Glutamine Transporter Slc38a1 Regulates GABAergic Neurotransmission and Synaptic Plasticity
por: Qureshi, Tayyaba, et al.
Publicado: (2019)

SLC1A5 provides glutamine and asparagine necessary for bone development in mice
por: Sharma, Deepika, et al.
Publicado: (2021)

Deficient glucose and glutamine metabolism in Aralar/AGC1/Slc25a12 knockout mice contributes to altered visual function
por: Contreras, Laura, et al.
Publicado: (2016)

Glutamine Addiction and Therapeutic Strategies in Lung Cancer
por: Vanhove, Karolien, et al.
Publicado: (2019)

Distinct effects of etoposide on glutamine-addicted neuroblastoma
por: Valter, Kadri, et al.
Publicado: (2019)

Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma
por: Peng, Yin-yin, et al.
Publicado: (2021)

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
por: Carreño, Leandro J, et al.
Publicado: (2016)

Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of MITD1
por: Dong, Shiqiang, et al.
Publicado: (2022)

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
por: Zhou, Qiming, et al.
Publicado: (2023)

Efficacy of Frontline Chemotherapy for Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Network Meta-Analysis
por: Luo, Fei, et al.
Publicado: (2023)

SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas
por: Wang, Peng, et al.
Publicado: (2020)

Lectin-like transcript 1 as a natural killer cell-mediated immunotherapeutic target for triple negative breast cancer and prostate cancer
por: Sun, Yuanhong, et al.
Publicado: (2019)

Glutamate and asparagine cataplerosis underlie glutamine addiction in melanoma
por: Ratnikov, Boris, et al.
Publicado: (2015)

TAp73 is a marker of glutamine addiction in medulloblastoma
por: Niklison-Chirou, Maria Victoria, et al.
Publicado: (2017)

Hopefully devoted to Q: targeting glutamine addiction in cancer
por: Still, Emma R, et al.
Publicado: (2017)

The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma
por: Bi, Xi-wen, et al.
Publicado: (2016)

Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies
por: Chouaib, Salem, et al.
Publicado: (2014)

Mitochondrial glutamine transporter SLC1A5_var, a potential target to suppress astrocyte reactivity in Parkinson’s Disease
por: Liu, Yang, et al.
Publicado: (2022)

A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
por: Tajan, Mylène, et al.
Publicado: (2018)

Slc38a1 Conveys Astroglia-Derived Glutamine into GABAergic Interneurons for Neurotransmitter GABA Synthesis
por: Qureshi, Tayyaba, et al.
Publicado: (2020)

Characterizing unexpected interactions of a glutamine transporter inhibitor with members of the SLC1A transporter family
por: Freidman, Natasha J., et al.
Publicado: (2022)

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
por: Cormerais, Yann, et al.
Publicado: (2018)

P1164: PEGARSPARGASE AND SINTILIMAB FOR NEWLY DIAGNOSED, ADVANCED STAGE NATURAL KILLER T-CELL LYMPHOMA, NASAL TYPE: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.
por: Xiong, Jie, et al.
Publicado: (2023)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jotr5c1e1859j73j8d286ntvbt